It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Induced pluripotent stem cell (iPSC) reprogramming is inefficient and understanding the molecular mechanisms underlying this inefficiency holds the key to successfully control cellular identity. Here, we report 24 reprogramming roadblock genes identified by CRISPR/Cas9-mediated genome-wide knockout (KO) screening. Of these, depletion of the predicted KRAB zinc finger protein (KRAB-ZFP) Zfp266 strongly and consistently enhances murine iPSC generation in several reprogramming settings, emerging as the most robust roadblock. We show that ZFP266 binds Short Interspersed Nuclear Elements (SINEs) adjacent to binding sites of pioneering factors, OCT4 (POU5F1), SOX2, and KLF4, and impedes chromatin opening. Replacing the KRAB co-suppressor with co-activator domains converts ZFP266 from an inhibitor to a potent facilitator of iPSC reprogramming. We propose that the SINE-KRAB-ZFP interaction is a critical regulator of chromatin accessibility at regulatory elements required for efficient cellular identity changes. In addition, this work serves as a resource to further illuminate molecular mechanisms hindering reprogramming.
Induced pluripotent stem cell (iPSC) reprogramming is inherently inefficient. Here the authors identify 24 reprogramming roadblock genes through a CRISPR/Cas9-mediated genome-wide knockout screen including a KRAB-ZFP Zfp266, knockout of which consistently enhances murine iPSC generation.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details





1 University of Edinburgh, Centre for Regenerative Medicine, Institute for Regenaration and Repair, Edinburgh, UK (GRID:grid.4305.2) (ISNI:0000 0004 1936 7988)
2 Karolinska Institutet, Department of Biosciences and Nutrition, Stockholm, Sweden (GRID:grid.4714.6) (ISNI:0000 0004 1937 0626); Chiba University, Institute for Advanced Academic Research, Chiba, Japan (GRID:grid.136304.3) (ISNI:0000 0004 0370 1101); Chiba University, Department of Artificial Intelligence Medicine, Graduate School of Medicine, Chiba, Japan (GRID:grid.136304.3) (ISNI:0000 0004 0370 1101)
3 Lund University, Computational Biology and Biological Physics, Lund, Sweden (GRID:grid.4514.4) (ISNI:0000 0001 0930 2361)
4 Karolinska Institutet, Department of Biosciences and Nutrition, Stockholm, Sweden (GRID:grid.4714.6) (ISNI:0000 0004 1937 0626); University of Helsinki, Research Programs Unit, Stem Cells and Metabolism Research Program (STEMM), Helsinki, Finland (GRID:grid.7737.4) (ISNI:0000 0004 0410 2071); Folkhälsan Research Center, Helsinki, Finland (GRID:grid.428673.c) (ISNI:0000 0004 0409 6302)
5 Kyoto University, Center for iPS Cell Research and Application, Kyoto, Japan (GRID:grid.258799.8) (ISNI:0000 0004 0372 2033)
6 Wellcome Sanger Institute, Stem Cell Genetics, Cambridge, UK (GRID:grid.10306.34) (ISNI:0000 0004 0606 5382); Kyoto University, Stem Cell Genetics, Institute for Life and Medical Sciences, Kyoto, Japan (GRID:grid.258799.8) (ISNI:0000 0004 0372 2033)